Volition announced a collaboration with Sysmex to optimize its Nu.Q NETs H3.1 circulating nucleosome-based assay on Sysmex analyzers. The assay quantifies H3.1-nucleosomes associated with neutrophil extracellular trap (NETosis), and elevated H3.1 nucleosomes have been linked to illness severity. The companies previously worked together to transfer Volition’s Nu.Q NETs tests to Sysmex systems; the new effort focuses on optimization for broader disease monitoring in NETosis-associated conditions. Volition said it has out-licensed its Nu.Q technology to large global partners to leverage their regulatory and installed-base strengths. For in vitro diagnostics developers, the move matters because NETosis biomarkers are increasingly targeted for point-of-care and routine hospital workflows—where analyzer compatibility and assay performance tradeoffs can determine adoption.